share_log

Altamira Therapeutics | F-1: Registration statement for securities of certain foreign private issuers

SEC announcement ·  Apr 10 08:17
Summary by Moomoo AI
Altamira Therapeutics Ltd., a preclinical-stage biopharmaceutical company, filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 10, 2024. The Bermuda-based company, operating under the industrial classification code number 2834, is registering common shares for a proposed sale to the public. The registration statement, identified by Registration No. 333-, is under the Securities Act of 1933. The company's principal executive offices are located in Hamilton, Bermuda, with Thomas Meyer, PhD, serving as the President. The commencement of the proposed sale is as soon as practicable after the effective date of the registration statement. Altamira Therapeutics Ltd. is also defined as a 'foreign private issuer' and is subject to reduced public company reporting requirements. The company plans to...Show More
Altamira Therapeutics Ltd., a preclinical-stage biopharmaceutical company, filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on April 10, 2024. The Bermuda-based company, operating under the industrial classification code number 2834, is registering common shares for a proposed sale to the public. The registration statement, identified by Registration No. 333-, is under the Securities Act of 1933. The company's principal executive offices are located in Hamilton, Bermuda, with Thomas Meyer, PhD, serving as the President. The commencement of the proposed sale is as soon as practicable after the effective date of the registration statement. Altamira Therapeutics Ltd. is also defined as a 'foreign private issuer' and is subject to reduced public company reporting requirements. The company plans to offer up to 2,000,000 common shares, par value USD 0.002 per share, for resale by the selling shareholder, Lincoln Park Capital Fund, LLC (LPC). Altamira will not sell any securities under this prospectus and will not receive proceeds from the resale by LPC. However, the company may receive up to $8,814,200 from the sale of Purchase Shares to LPC under a purchase agreement. LPC is considered an 'underwriter' within the meaning of the Securities Act. The common shares are traded on The Nasdaq Capital Market under the symbol 'CYTO', with a closing price of $1.975 per share as of April 5, 2024. The company emphasizes the high degree of risk involved in investing in their common shares.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Doc 4

Doc 5

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more